SetPoint was co-founded by neurosurgeon Kevin Tracey, chief executive of Feinstein Institute for Medical Research and professor at and president of the Elmezzi Graduate School of Molecular Medicine in Manhasset, New York.

UK-listed drugs company GlaxoSmithKline’s (GSK) new strategic corporate venturing fund for bioelectronic medicines and technologies has joined a consortium to investing in the $27m series D round for SetPoint Medical, a US-based biomedical technology company.

Alongside GSK’s Action Potential Venture Capital fund in the round were corporate venturing peers from healthcare companies Covidien and Boston Scientific and venture capital firms Morgenthaler Ventures, Foundation Medical Partners, which as Cleveland Clinic as a strategic limited partner, and Topspin Partners.

The three venture…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?